Conference Call/Webcast Today at
Key Highlights
- Completed the first commercial placement of its flagship Perimeter S-Series OCT system in the state of
Utah - Initiated an additional clinical trial site at
Baptist MD Anderson Cancer Center inJacksonville, FL - Appointed global industry leader
Suzanne Foster – currently President of Beckman Coulter Life Sciences – as Chair of its Board of Directors - Showcased Perimeter S-Series OCT at leading industry conferences including SSO 2023 and ASBrS 2023
First Quarter Update
- In
January 2023 , Perimeter announced the completion of two follow-on commercial placements of Perimeter S-Series OCT, resulting in a doubling of the commercial installed base of S-Series OCT during the fourth quarter 2022. Subsequent to quarter-end, Perimeter completed the first commercial placement of its flagship Perimeter S-Series OCT system in the state ofUtah . - Led by Principal Investigator, Dr.
Alastair Thompson at theBaylor College of Medicine inHouston , a multi-center, randomized two-arm pivotal clinical trial is evaluating Perimeter B-Series OCT combined with its proprietary ImgAssist AI software in approximately 330 patients, with study completion anticipated by the end of 2023. Subsequent to quarter-end, Perimeter initiated an additional clinical trial site atBaptist MD Anderson Cancer Center inJacksonville, FL to further support patient enrollment. - Perimeter announced the appointment of global industry leader
Suzanne Foster – currently President of Beckman Coulter Life Sciences – as Chair of its Board of Directors, which is comprised of world-class life sciences, medtech, and AI experts, includingAnantha Kancherla of Meta. - Perimeter announced the publication of a white paper from three case studies from the commercial use of its Perimeter S-Series OCT technology. The supporting clinical evidence suggests that the surgeon's use of the S-Series aided in intraoperative clinical decisions to excise additional tissue during the primary surgeries, sparing the need for a second surgery and relieving the associated burden on clinical, economic, and psychosocial resources.
- Perimeter conducted multiple clinical presentations and product demonstrations showcasing Perimeter S-Series OCT at several leading industry events and conferences including:
- SSO 2023, the
Society of Surgical Oncology's International Conference on Surgical Cancer Care , featuring a spotlight presentation by Dr. Shawndeep Singh Tung and Dr.Nina Tamirisa . - ASBrS 2023, the 24th Annual Meeting of the
American Society of Breast Surgeons , including a symposium and panel discussion with Dr.Beth Anglin and Dr.Michele Carpenter moderated by Dr.Beth DuPree .
Summary of First Quarter 2023 Financial Results
All of the amounts are expressed in
The Company changed its presentation currency from Canadian dollars to
Operating expenses for the three months ended
For the three months ended
For the three months ended
As at
For detailed financial results, please see Perimeter's filings at www.sedar.com and on the Company's website at https://ir.perimetermed.com/.
Conference Call
The Company will host a conference call and live audio webcast today,
About
Based in
Neither the
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter's expected marketing and sales activities; and the expected details regarding Perimeter's ongoing clinical trials, including anticipated improvements in patient enrollment rates and the estimated completion date of enrollment, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended
View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-reports-first-quarter-2023-financial-results-and-provides-corporate-update-301835107.html
SOURCE
© Canada Newswire, source